Aortic Stenosis in Women: A Different Disease in the Same Valve

Aortic stenosis is not a single disease experienced identically by every patient. In women, the biology of how calcium accumulates on the valve, how the heart adapts to obstruction, and how symptoms appear before diagnosis all follow a pattern that is meaningfully different from what is observed in men. Recognizing those differences is not a minor clinical footnote; it has direct implications for when to refer, which procedure to choose, and how to interpret echocardiographic numbers that may look deceptively reassuring.

How Common Is Aortic Stenosis, and Who Gets It

Aortic stenosis is the most common valvular heart disease requiring intervention in high-income countries. Prevalence rises sharply with age, affecting roughly 2 to 5 percent of adults over 65 and approaching 10 percent in those over 80. In broad epidemiological terms, the condition affects older men and women in roughly equal numbers, though the path each group takes to diagnosis looks quite different.

Men more commonly develop aortic stenosis in the context of a bicuspid aortic valve, a congenital anomaly present in about 1 to 2 percent of the population and roughly three times more prevalent in men. Women, in contrast, more commonly develop calcific degeneration of a trileaflet valve as the primary mechanism, and this tends to occur at older ages. The result is that women often arrive at a valve clinic years older than their male counterparts and frequently with more advanced myocardial remodeling already in place.

The Biology of Calcification Differs by Sex

The evidence shows that calcification of the aortic valve proceeds through somewhat different pathways depending on sex. In men, the process more closely resembles atherosclerotic plaque development, with lipid infiltration and inflammation playing prominent roles. In women, fibrosis and calcification appear to be more dominant, with less lipid involvement. This distinction may help explain why lipid-lowering therapy, despite appearing promising in earlier observational studies, has not been shown to slow valve stenosis progression in randomized trials.

The practical consequence is that the valve in a woman may look less calcified on imaging while still being significantly obstructed. Some cardiologists note that visual calcification scores on echocardiography can underestimate severity in women, and that computed tomography calcium scoring of the valve, which directly quantifies calcium burden, may offer a more sex-equitable method of grading stenosis.

Cardiac Remodeling: Thick Walls Instead of Big Chambers

Perhaps the most clinically important sex difference in aortic stenosis is what the heart does in response to the pressure overload. Men tend to develop eccentric hypertrophy, meaning the heart enlarges and dilates as the left ventricle tries to handle the increased workload over time. Women, by contrast, overwhelmingly develop concentric remodeling: the wall thickens while the chamber cavity remains small or even shrinks. Ejection fraction, the number most clinicians use to gauge pump function, may remain preserved or even appear supernormal.

This pattern means women can have severely impaired diastolic function, elevated filling pressures, and significant heart failure symptoms while their ejection fraction reads 60 or 65 percent. The downstream consequence is heart failure with preserved ejection fraction, or HFpEF, which is far more common in women with aortic stenosis than in men. Attributing dyspnea to HFpEF or deconditioning without adequately evaluating the valve is a diagnostic error that delays appropriate intervention.

Women Present Later and with Different Symptoms

The classic triad of aortic stenosis symptoms, angina, syncope, and heart failure, is taught as a unified package, but women and men do not reach these symptoms on the same timeline or with the same constellation. Evidence from large valve registries suggests that women present at the time of intervention with more severe symptoms, smaller indexed valve areas, and higher transvalvular gradients relative to body size, compared with men. This pattern implies a longer interval between the onset of hemodynamically significant stenosis and the point at which clinical attention is paid.

Part of this delay may reflect symptom differences. Women with aortic stenosis more commonly report progressive exertional dyspnea and fatigue as their primary complaints. These symptoms are nonspecific and are frequently attributed to deconditioning, anxiety, anemia, or pulmonary causes before the valve is considered. Chest tightness with exertion, ankle swelling, and lightheadedness on standing are also reported more often in women than classical effort angina. A careful history that specifically asks about activity limitation over the preceding 6 to 12 months is more likely to surface the diagnosis than waiting for a patient to volunteer classic angina symptoms.

Paradoxical Low-Flow, Low-Gradient Aortic Stenosis

A particularly treacherous diagnostic subset is paradoxical low-flow, low-gradient aortic stenosis, a pattern that is substantially more common in women than in men. In this presentation, the ejection fraction is preserved, but the stroke volume index is low, meaning the heart is not pushing enough blood across the valve per beat relative to body size. The result is that pressure gradients across the valve appear modest, often below the threshold that triggers a severe classification, despite genuinely severe stenosis by valve area criteria.

This condition is frequently missed or undertreated because the hemodynamic numbers do not trigger the same clinical alarm as high-gradient severe aortic stenosis. Women are at disproportionate risk of being told their valve is “moderate” when the small body size, low stroke volume, and preserved ejection fraction are all combining to produce misleadingly low gradients. Using stroke volume index and indexed valve area, both normalized to body surface area, is essential to avoid this error in smaller women.

Indexed Valve Area and the Sizing Problem

Standard echocardiographic criteria define severe aortic stenosis as a valve area below 1.0 square centimeters. However, a woman weighing 50 kilograms and a man weighing 100 kilograms do not have equivalent hemodynamic demands from a 0.9 square centimeter orifice. Indexing the valve area to body surface area, and using a threshold of approximately 0.6 square centimeters per square meter, provides a more biologically meaningful number for small-framed patients, the majority of whom are women.

Some cardiologists advocate routinely reporting both absolute and indexed valve areas in echocardiographic assessments of all patients, precisely because the non-indexed number can be misinterpreted in women with smaller body size. Failure to index appropriately may result in women being classified as having moderate stenosis when they in fact meet physiologic criteria for severe disease.

Bicuspid Aortic Valve in Women: A Different Risk Profile

Although bicuspid aortic valve is roughly three times more common in men, women who carry this congenital anomaly face a distinct set of challenges. The evidence shows that women with bicuspid valves develop aortic stenosis at a younger age than men with the same anomaly, and they often present with smaller annular dimensions. This anatomical reality complicates both surgical and transcatheter approaches.

Women with bicuspid valves undergoing transcatheter aortic valve replacement face a higher technical challenge because of the oval or asymmetric annular geometry and the smaller overall dimensions. Rates of permanent pacemaker implantation and annular injury may be modestly higher in this population. For younger women with bicuspid valves and isolated severe stenosis without significant calcification or annular distortion, surgical aortic valve replacement with a durable mechanical valve or a high-quality bioprosthesis may remain the preferred approach after careful heart team discussion.

What the PARTNER Trials Showed About Sex

The PARTNER trial program, spanning PARTNER 1, PARTNER 2, and PARTNER 3, provided the foundational evidence base for transcatheter aortic valve replacement and included sex-specific analyses that have shaped current practice. A consistent pattern emerged across these trials: women who underwent surgical aortic valve replacement had higher 30-day mortality than men undergoing the same procedure, a finding that held across surgical risk categories.

In contrast, women who underwent TAVR in these trials had 30-day and one-year outcomes that were equivalent to or better than men undergoing TAVR. 5 / Solid The crossover in outcomes, where women fare worse with surgery but not with TAVR, has been observed in multiple analyses and has informed a growing clinical consensus that TAVR is the preferred approach for most women with severe aortic stenosis who meet anatomical eligibility criteria.

The reasons women fare worse with open surgery are not entirely settled, but contributing factors likely include smaller body size increasing technical complexity, higher rates of patient-prosthesis mismatch with surgically implanted valves, and potentially hormonal and inflammatory differences in the surgical stress response.

Post-TAVR Outcomes: Women Live Longer

A perhaps surprising finding from large real-world registries is that women appear to have better long-term survival after TAVR than men. Data from the Transcatheter Valve Therapy Registry (TVT Registry), which captures virtually all commercial TAVR procedures in the United States, and from the STS/ACC national database have both shown that women who survive to discharge after TAVR have lower subsequent mortality rates than men at one and two years post-procedure. 4 / Promising

This survival advantage after TAVR may reflect the superior myocardial reserve that concentric remodeling preserves in some women, as well as the reversal of the afterload burden on a heart that has maintained its pump function. It reinforces the message that women who are appropriately referred and appropriately treated with TAVR stand to gain substantially from the intervention.

Symptoms That Should Not Be Dismissed

Several symptoms reported by women with aortic stenosis are commonly attributed to other causes before the valve is considered. Progressive exertional dyspnea that has worsened over 12 months, particularly in a woman over 65, warrants an echocardiogram. Chest tightness or heaviness with physical exertion, even mild exertion such as climbing one flight of stairs, should prompt valve evaluation. Ankle swelling in the absence of venous insufficiency or a clear medication cause may reflect elevated left heart pressures from diastolic dysfunction related to valve disease.

Lightheadedness on standing, or a sense of near-fainting during or after exertion, can reflect effort syncope from fixed cardiac output across a narrowed valve. Women may describe this as a vague sense of weakness or needing to sit down rather than a classic near-blackout, and the symptom may be dismissed as orthostatic hypotension or vasovagal tendency before the valve is evaluated.

Clinicians who see women in this age range should maintain a lower threshold for echocardiographic assessment when any of these symptoms are present, particularly if they are progressive and unexplained by another clear cause.

The Heart Team and Surgical Risk Calculators

When a woman with severe aortic stenosis reaches the point of intervention planning, risk estimation becomes critical. The STS Predicted Risk of Mortality calculator and similar tools have known limitations in women. Several analyses have shown that these calculators systematically underestimate perioperative surgical mortality in women, possibly because the female patient populations in the historical datasets were smaller and their outcomes less well characterized.

This underestimation matters because a woman calculated to be at low surgical risk may in fact face a meaningfully higher procedural mortality than her male counterpart with an identical score. Heart teams that are aware of this limitation can apply clinical judgment to recommend TAVR in women who might otherwise be borderline candidates for surgery on the basis of calculator output alone.

Living with Aortic Stenosis Before Intervention

For women with moderate or asymptomatic severe aortic stenosis who are not yet at the intervention threshold, surveillance is the current standard. Guidelines recommend echocardiographic follow-up at 3 to 5 year intervals for mild stenosis, 1 to 2 year intervals for moderate stenosis, and 6 to 12 month intervals for severe asymptomatic stenosis, with closer monitoring if any new symptoms develop.

Physical activity guidance during this period is nuanced. Vigorous competitive exercise is generally discouraged in severe stenosis because of the fixed cardiac output limitation. However, moderate aerobic activity appears safe in most asymptomatic patients with severe stenosis and may preserve overall conditioning ahead of intervention. Women should discuss individualized activity guidance with their cardiologist, as blanket exercise restriction without a clear indication may worsen deconditioning and reduce quality of life unnecessarily.

Monitoring and Follow-Up After TAVR

After TAVR, women require echocardiographic follow-up to assess valve function, rule out paravalvular leak, and monitor for structural valve deterioration over time. The durability of transcatheter valves beyond 10 years is an active area of study, and because women who undergo TAVR are often older at the time of procedure, the lifetime risk of valve deterioration is lower than for younger patients.

Anticoagulation and antiplatelet decisions after TAVR should account for bleeding risk, which may differ between men and women on the basis of body size and renal function. Women who are already on anticoagulation for atrial fibrillation, a common comorbidity in older patients with aortic stenosis, will have their TAVR antiplatelet regimen guided by that underlying indication.

Valve Choice After TAVR: Bioprosthesis Durability and Future Options

One practical consideration for women undergoing valve intervention is the longevity of the implanted valve and the implications for future reinterventions. All bioprosthetic valves, both surgical and transcatheter, undergo structural deterioration over time. The rate of deterioration is influenced by age at implantation, with younger patients experiencing faster degeneration due to higher metabolic activity and longer expected remaining lifespan.

For women who undergo TAVR in their late 70s or early 80s, which is the most common age range for transcatheter intervention in this population, the risk of structural valve deterioration within their expected remaining lifetime is relatively low. For younger women, particularly those under 70 who are undergoing TAVR because of prohibitive surgical risk or anatomical preference, the question of valve-in-valve feasibility becomes relevant. If a transcatheter valve were to degenerate after 10 to 15 years, a subsequent transcatheter valve-in-valve procedure may be possible depending on the original valve dimensions and coronary anatomy.

Heart teams caring for women in the younger TAVR age range should discuss valve durability and future options as part of the pre-procedural consent and planning conversation. This ensures that the choice of transcatheter valve size and type is made with an awareness of long-term management implications, not only immediate hemodynamic outcomes.

Frailty and Functional Assessment in Older Women

Older women presenting for valve intervention are more likely than older men to have frailty as a complicating factor. Frailty, a state of reduced physiological reserve and resilience across multiple organ systems, is associated with worse outcomes after both surgical and transcatheter aortic valve procedures. Standard surgical risk calculators do not adequately capture frailty, which is one more reason they may underestimate risk in older women.

Several validated frailty assessment tools, including the Clinical Frailty Scale, the Fried frailty phenotype, and the Essential Frailty Toolset specifically developed for structural heart intervention, can be incorporated into the pre-procedural workup. Some heart programs routinely include a formal frailty assessment as part of the valve clinic evaluation. The evidence shows that women with moderate frailty can still derive meaningful benefit from TAVR, particularly in terms of symptom relief and quality of life improvement, even when survival benefit is more uncertain. The symptom burden of untreated severe aortic stenosis in a frail older woman is itself substantial, and quality-of-life goals should be an explicit part of the treatment conversation.

Prehabilitation, a structured program of supervised exercise and nutritional improvement before an elective procedure, is an emerging strategy for women with mild to moderate frailty who are awaiting TAVR. Small studies suggest that prehabilitation may improve functional outcomes and reduce post-procedural complications, though the evidence base is still developing.

A Disease That Demands Sex-Aware Care

Aortic stenosis in women is not simply a smaller version of the disease in men. The calcification biology differs, the cardiac remodeling differs, the symptom presentation is frequently atypical for what guidelines were written to capture, and the procedural risk profile favors a catheter-based approach in most eligible women. Recognizing these differences at every step, from initial echocardiographic interpretation to intervention planning to post-procedural follow-up, is what allows women with this condition to receive care that is genuinely calibrated to their physiology rather than benchmarked against a predominantly male evidence base.

Evidence continues to accumulate, and ongoing registries and trials are capturing sex-specific data with increasing rigor. The trajectory is toward an evidence base that reflects the biology of the population it serves, but the clinical responsibility to apply existing sex-aware knowledge remains immediate and actionable today.

The Women’s Signal Check is fifteen questions mapping the female cardiovascular risk pattern, including reproductive history, microvascular signals, and the factors standard risk calculators do not capture. It produces a specific starting point for your next clinical conversation.